P53 Modeling as a Route to Mesothelioma Patients Stratification and Novel Therapeutic Identification

Journal of Translational Medicine - United Kingdom
doi 10.1186/s12967-018-1650-0
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Gli as a Novel Therapeutic Target in Malignant Pleural Mesothelioma

PLoS ONE
Multidisciplinary
2013English

Inhibition of the Spindle Assembly Checkpoint Kinase MPS-1 as a Novel Therapeutic Strategy in Malignant Mesothelioma

Oncogene
Cancer ResearchGeneticsMolecular Biology
2017English

Quinols as Novel Therapeutic Agents. 8. Applications of the Sonogashira Route to Thioredoxin-Inhibitory Indolyl-Substituted Quinols

Arkivoc
Organic Chemistry
2007English

Aurora-A Overexpression Reveals Tetraploidization as a Major Route to Centrosome Amplification in P53-/- Cells

EMBO Journal
ImmunologyMolecular BiologyBiochemistryMicrobiology NeuroscienceMedicineGenetics
2002English

P1.02-052 Identification of DAB2 and Intelectin-1 as Novel Positive Immunohistochemical Markers of Epithelioid Mesothelioma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

Identification of Novel Blood Biomarker Panels to Detect Ischemic Stroke in Patients and Their Responsiveness to Therapeutic Intervention

Brain Research
NeuroscienceNeurologyDevelopmental BiologyMolecular Biology
2018English

GPR35 as a Novel Therapeutic Target

Frontiers in Endocrinology
EndocrinologyMetabolismDiabetes
2011English

P2.06-20 Bacteria as Novel Anti-Mesothelioma Agents.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Identification of TRIML2, a Novel P53 Target, That Enhances P53 SUMOylation and Regulates the Transactivation of Proapoptotic Genes

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy